Get the Stockscreener App
0.3084
1.67%
0.00505
IGC Pharma Inc stock is traded at $0.3084, with a volume of 240.84K.
It is up +1.67% in the last 24 hours and down -10.62% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.3033
Open:
$0.31
24h Volume:
240.84K
Relative Volume:
0.62
Market Cap:
$20.26M
Revenue:
$1.22M
Net Income/Loss:
$-14.15M
P/E Ratio:
-1.186
EPS:
-0.26
Net Cash Flow:
$-6.55M
1W Performance:
-3.58%
1M Performance:
-10.62%
6M Performance:
-20.12%
1Y Performance:
+4.56%
1-Day Range:
$0.306
$0.3162
1-Week Range:
$0.3006
$0.3281
52-Week Range:
$0.27
$0.9099
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.3084 | 20.26M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.57 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.57 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.51 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.28 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
IGC Pharma Inc Stock (IGC) Latest News
Market Recap: IGC Pharma Inc (IGC)’s Positive Momentum, Closing at 0.32 - The Dwinnex
Page 3 | IGC PHARMA INC Trade Ideas — TRADEGATE:IGS1 - TradingView
IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease - Joplin Globe
Revolutionary Voice AI Could Detect Alzheimer's Before Symptoms ShowIGC's Breakthrough - StockTitan
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline - ACCESS Newswire
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy - ACCESS Newswire
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies - ACCESS Newswire
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge - ACCESS Newswire
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor - Markets Insider
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 - AccessWire
Geode Capital Management LLC Has $240,000 Stock Holdings in IGC Pharma, Inc. (NYSEMKT:IGC) - Defense World
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets - Big News Network
IGC Pharma to Unveil Alzheimer's Pipeline and AI Drug Discovery Updates at Investor Chat - StockTitan
Amazon To Sell Ad Tools To Third Parties - Baystreet.ca
IGC Gains on Word of Alzheimer’s Treatment - Baystreet.ca
IGC Pharma's CALMA Trial Triples Alzheimer's Patient Recruitment with AI-Powered Strategy - StockTitan
IGC Pharma to Present at BIO Partnering @ JPM 2025 Healthcare Conference - StockTitan
What Makes IGC Pharma, Inc. (IGC) a New Buy Stock - MSN
Ascendiant Capital Markets Forecasts Strong Price Appreciation for IGC Pharma (NYSEMKT:IGC) Stock - Defense World
IGC Pharma expands clinical research program for IGC-AD1 - Nasdaq
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology - AccessWire
IGC Pharma's Alzheimer's Drug Shows 50% Memory Improvement in Early Studies - StockTitan
IGC.WS (India Globalization Capital) EV-to-FCF : 0.00 (As of Nov. 30, 2024) - GuruFocus.com
Otsuka Corp (OSUKF) QuotePress Release - The Globe and Mail
Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial - Inkl
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment - BioSpace
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of He - GuruFocus.com
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasin - GuruFocus.com
IGC (IGC Pharma) Price-to-Operating-Cash-Flow : (As of Nov. 14, 2024) - GuruFocus.com
IGC Pharma Reports 42% Revenue Growth, Advances Multiple Alzheimer's Drug Candidates - StockTitan
IGC Pharma CEO Reveals AI-Driven Strategy in Alzheimer's and Weight Loss Drug Development | IGC Stock News - StockTitan
IGC Pharma (STU:IGS1) Asset Turnover : 0.03 (As of Jun. 2024) - GuruFocus.com
MD’s IGC Pharma enrolls patients in Phase 2 trial for Alzheimer’s dementia drug - Maryland Daily Record
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 - AccessWire
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):